Seres Therapeutics (MCRB) Competitors $9.70 +0.30 (+3.19%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB vs. SEPN, MBX, AQST, ITOS, CMPX, AVIR, TERN, ACB, SLDB, and ATXSShould you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Septerna (SEPN), MBX Biosciences (MBX), Aquestive Therapeutics (AQST), iTeos Therapeutics (ITOS), Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), Terns Pharmaceuticals (TERN), Aurora Cannabis (ACB), Solid Biosciences (SLDB), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Seres Therapeutics vs. Septerna MBX Biosciences Aquestive Therapeutics iTeos Therapeutics Compass Therapeutics Atea Pharmaceuticals Terns Pharmaceuticals Aurora Cannabis Solid Biosciences Astria Therapeutics Septerna (NASDAQ:SEPN) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment. Do insiders & institutionals believe in SEPN or MCRB? 59.3% of Seres Therapeutics shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer SEPN or MCRB? Septerna presently has a consensus target price of $33.00, suggesting a potential upside of 374.14%. Seres Therapeutics has a consensus target price of $80.00, suggesting a potential upside of 724.74%. Given Seres Therapeutics' higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community believe in SEPN or MCRB? Seres Therapeutics received 526 more outperform votes than Septerna when rated by MarketBeat users. However, 71.43% of users gave Septerna an outperform vote while only 71.18% of users gave Seres Therapeutics an outperform vote. CompanyUnderperformOutperformSepternaOutperform Votes571.43% Underperform Votes228.57% Seres TherapeuticsOutperform Votes53171.18% Underperform Votes21528.82% Which has higher earnings & valuation, SEPN or MCRB? Septerna has higher earnings, but lower revenue than Seres Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$1.08M287.74N/AN/AN/ASeres Therapeutics$126.33M0.67-$113.72M-$4.60-2.11 Does the media favor SEPN or MCRB? In the previous week, Seres Therapeutics had 3 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Seres Therapeutics and 4 mentions for Septerna. Septerna's average media sentiment score of 1.52 beat Seres Therapeutics' score of 0.46 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Seres Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is SEPN or MCRB more profitable? Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Seres Therapeutics N/A N/A -55.08% SummarySepterna and Seres Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCRB vs. The Competition Export to ExcelMetricSeres TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.57M$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-42.177.4422.4418.48Price / Sales0.67242.70394.09103.59Price / CashN/A65.8538.1834.62Price / Book-27.716.516.774.25Net Income-$113.72M$143.21M$3.22B$248.23M7 Day Performance6.83%1.98%1.49%0.89%1 Month Performance-28.28%6.89%4.00%3.53%1 Year Performance-55.09%-2.52%16.21%5.08% Seres Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCRBSeres Therapeutics3.3352 of 5 stars$9.70+3.2%$80.00+724.7%-51.0%$84.57M$126.33M-42.17330Upcoming EarningsAnalyst DowngradeNews CoverageSEPNSepterna2.257 of 5 stars$5.87-0.5%$33.00+462.2%N/A$260.88M$1.08M0.00N/ANews CoveragePositive NewsMBXMBX Biosciences2.4915 of 5 stars$7.64+0.3%$37.50+390.8%N/A$255.36MN/A0.0036AQSTAquestive Therapeutics1.5117 of 5 stars$2.58+2.8%$10.67+313.4%-13.1%$255.09M$57.56M-5.73160Upcoming EarningsITOSiTeos Therapeutics2.0927 of 5 stars$6.62+1.7%$25.75+289.0%-32.5%$252.84M$35M-2.1090Earnings ReportAnalyst ForecastNews CoverageCMPXCompass Therapeutics3.3847 of 5 stars$1.78+1.7%$13.38+651.4%+29.2%$246.14M$850,000.00-4.8120Analyst ForecastShort Interest ↑AVIRAtea Pharmaceuticals3.1159 of 5 stars$2.86-3.7%$6.00+109.8%-20.3%$244.60MN/A-1.3870TERNTerns Pharmaceuticals4.2642 of 5 stars$2.71+12.9%$18.38+578.0%-34.7%$236.58MN/A-2.3040Positive NewsACBAurora Cannabis0.6453 of 5 stars$4.20-5.4%N/A-49.7%$236.10M$320.81M84.021,340News CoverageSLDBSolid Biosciences3.9851 of 5 stars$3.03+18.8%$15.67+417.1%-62.7%$234.80M$8.09M-1.00100High Trading VolumeATXSAstria Therapeutics2.8114 of 5 stars$4.11+1.7%$26.60+547.2%-43.8%$231.94MN/A-1.9730Upcoming EarningsAnalyst ForecastNews Coverage Related Companies and Tools Related Companies SEPN Competitors MBX Competitors AQST Competitors ITOS Competitors CMPX Competitors AVIR Competitors TERN Competitors ACB Competitors SLDB Competitors ATXS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MCRB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MCRB Stock Free MCRB Stock Alerts